This disclosure concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the disclosure concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, in combination with one or more additional anti-tumor therapeutic agents in previously treated metastatic breast cancer.